Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
Full text not available from this repository.Item Type: | Review |
---|---|
Status: | Published |
Official URL: | https://doi.org/10.3390/cancers13163932 |
Journal or Publication Title: | Cancers |
Volume: | 13 |
Number: | 16 |
Page Range: | p. 3932 |
Date: | 4 August 2021 |
Divisions: | Gene and Stem Cell Therapy |
Depositing User: | General Admin |
Identification Number: | 10.3390/cancers13163932 |
ISSN: | 2072-6694 |
Date Deposited: | 10 Oct 2021 10:46 |
Abstract: | Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM. Many other solid cancers overexpress MSLN, and this is associated with worse survival rates. However, this association has not been found in MPM, and the exact biological role of MSLN in MPM requires further exploration. Here, we discuss the current research on the diagnostic and prognostic value of MSLN in MPM patients. Furthermore, MSLN has become an attractive immunotherapy target in MPM, where better treatment strategies are urgently needed. Several MSLN-targeted monoclonal antibodies, antibody-drug conjugates, immunotoxins, cancer vaccines, and cellular therapies have been tested in the clinical setting. The biological rationale underpinning MSLN-targeted immunotherapies and their potential to improve MPM patient outcomes are reviewed. Keywords: CAR T cells; biomarker; cancer; immunotherapy; malignant mesothelioma; malignant pleural mesothelioma; mesothelin; therapeutic target. |
Creators: | Creators Email Yeo, Dannel UNSPECIFIED Castelletti, Laura UNSPECIFIED van Zandwijk, Nico UNSPECIFIED Rasko, John E. J. UNSPECIFIED |
Last Modified: | 10 Oct 2021 10:46 |
URI: | https://eprints.centenary.org.au/id/eprint/1084 |
Actions (login required)
![]() |
View Item |